 | • レポートコード：MRC2Q12-19006 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、口腔乾燥症治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 口腔乾燥症治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 口腔乾燥症治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 口腔乾燥症治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの口腔乾燥症治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の口腔乾燥症治療薬の売上および2028年までの予測に焦点を当てています。 口腔乾燥症治療薬のグローバル主要企業には、Concordia、AMICI、Aurobindo Pharma Ltd、Impax Labs、Lannett Co Inc、Padagis Us、Amneal Pharmaceuticals Pvt. Ltd.、Bausch Health Companies Inc.、GSK、Jazz Pharmaceuticals plc、Mission Pharmacal Company、OraCoat、Cumberland Pharmaceuticals, Inc.、Fleet, C.B., Company、Parnell Pharmaceuticals, Inc、Clinigen、Sun Pharmなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 口腔乾燥症治療薬市場は、タイプとアプリケーションによって区分されます。世界の口腔乾燥症治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 スプレー、経口液、口腔錠、うがい薬 【アプリケーション別セグメント】 スーパーマーケット、病院、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 口腔乾燥症治療薬製品概要 - タイプ別市場（スプレー、経口液、口腔錠、うがい薬） - アプリケーション別市場（スーパーマーケット、病院、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の口腔乾燥症治療薬販売量予測2017-2028 - 世界の口腔乾燥症治療薬売上予測2017-2028 - 口腔乾燥症治療薬の地域別販売量 - 口腔乾燥症治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別口腔乾燥症治療薬販売量 - 主要メーカー別口腔乾燥症治療薬売上 - 主要メーカー別口腔乾燥症治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（スプレー、経口液、口腔錠、うがい薬） - 口腔乾燥症治療薬のタイプ別販売量 - 口腔乾燥症治療薬のタイプ別売上 - 口腔乾燥症治療薬のタイプ別価格 ・アプリケーション別市場規模（スーパーマーケット、病院、その他） - 口腔乾燥症治療薬のアプリケーション別販売量 - 口腔乾燥症治療薬のアプリケーション別売上 - 口腔乾燥症治療薬のアプリケーション別価格 ・北米市場 - 北米の口腔乾燥症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の口腔乾燥症治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの口腔乾燥症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の口腔乾燥症治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の口腔乾燥症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の口腔乾燥症治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の口腔乾燥症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の口腔乾燥症治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの口腔乾燥症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の口腔乾燥症治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Concordia、AMICI、Aurobindo Pharma Ltd、Impax Labs、Lannett Co Inc、Padagis Us、Amneal Pharmaceuticals Pvt. Ltd.、Bausch Health Companies Inc.、GSK、Jazz Pharmaceuticals plc、Mission Pharmacal Company、OraCoat、Cumberland Pharmaceuticals, Inc.、Fleet, C.B., Company、Parnell Pharmaceuticals, Inc、Clinigen、Sun Pharm ・産業チェーン及び販売チャネル分析 - 口腔乾燥症治療薬の産業チェーン分析 - 口腔乾燥症治療薬の原材料 - 口腔乾燥症治療薬の生産プロセス - 口腔乾燥症治療薬の販売及びマーケティング - 口腔乾燥症治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 口腔乾燥症治療薬の産業動向 - 口腔乾燥症治療薬のマーケットドライバー - 口腔乾燥症治療薬の課題 - 口腔乾燥症治療薬の阻害要因 ・主な調査結果 |
Drugs for Xerostomia include prescription and over-the-counter mouthwashes, artificial saliva or humectants to moisturize the mouth, mouthwashes specially for dry mouth, especially those containing xylitol
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Drugs for Xerostomia is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Drugs for Xerostomia is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Drugs for Xerostomia is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Drugs for Xerostomia include Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs, Lannett Co Inc, Padagis Us, Amneal Pharmaceuticals Pvt. Ltd., Bausch Health Companies Inc. and GSK, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Drugs for Xerostomia manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Drugs for Xerostomia market. Further, it explains the major drivers and regional dynamics of the global Drugs for Xerostomia market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Drugs for Xerostomia Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Drugs for Xerostomia Segment by Application
Supermarket
Hospital
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Drugs for Xerostomia market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Drugs for Xerostomia, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Drugs for Xerostomia, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Drugs for Xerostomia, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drugs for Xerostomia sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Drugs for Xerostomia market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Drugs for Xerostomia sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs, Lannett Co Inc, Padagis Us, Amneal Pharmaceuticals Pvt. Ltd., Bausch Health Companies Inc. and GSK, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Drugs for Xerostomia in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Drugs for Xerostomia manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Xerostomia sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Drugs for Xerostomia Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Xerostomia Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Spray
1.2.3 Oral Liquid
1.2.4 Buccal Tablet
1.2.5 Mouth Wash
1.3 Market by Application
1.3.1 Global Drugs for Xerostomia Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Supermarket
1.3.3 Hospital
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Xerostomia Sales Estimates and Forecasts 2017-2028
2.2 Global Drugs for Xerostomia Revenue Estimates and Forecasts 2017-2028
2.3 Global Drugs for Xerostomia Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Drugs for Xerostomia Sales by Region
2.4.1 Global Drugs for Xerostomia Sales by Region (2017-2022)
2.4.2 Global Sales Drugs for Xerostomia by Region (2023-2028)
2.5 Global Drugs for Xerostomia Revenue by Region
2.5.1 Global Drugs for Xerostomia Revenue by Region (2017-2022)
2.5.2 Global Drugs for Xerostomia Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Drugs for Xerostomia Sales by Manufacturers
3.1.1 Global Top Drugs for Xerostomia Manufacturers by Sales (2017-2022)
3.1.2 Global Drugs for Xerostomia Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Drugs for Xerostomia in 2021
3.2 Global Drugs for Xerostomia Revenue by Manufacturers
3.2.1 Global Drugs for Xerostomia Revenue by Manufacturers (2017-2022)
3.2.2 Global Drugs for Xerostomia Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Drugs for Xerostomia Revenue in 2021
3.3 Global Drugs for Xerostomia Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Drugs for Xerostomia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Drugs for Xerostomia Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Drugs for Xerostomia Sales by Type
4.1.1 Global Drugs for Xerostomia Historical Sales by Type (2017-2022)
4.1.2 Global Drugs for Xerostomia Forecasted Sales by Type (2023-2028)
4.1.3 Global Drugs for Xerostomia Sales Market Share by Type (2017-2028)
4.2 Global Drugs for Xerostomia Revenue by Type
4.2.1 Global Drugs for Xerostomia Historical Revenue by Type (2017-2022)
4.2.2 Global Drugs for Xerostomia Forecasted Revenue by Type (2023-2028)
4.2.3 Global Drugs for Xerostomia Revenue Market Share by Type (2017-2028)
4.3 Global Drugs for Xerostomia Price by Type
4.3.1 Global Drugs for Xerostomia Price by Type (2017-2022)
4.3.2 Global Drugs for Xerostomia Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Drugs for Xerostomia Sales by Application
5.1.1 Global Drugs for Xerostomia Historical Sales by Application (2017-2022)
5.1.2 Global Drugs for Xerostomia Forecasted Sales by Application (2023-2028)
5.1.3 Global Drugs for Xerostomia Sales Market Share by Application (2017-2028)
5.2 Global Drugs for Xerostomia Revenue by Application
5.2.1 Global Drugs for Xerostomia Historical Revenue by Application (2017-2022)
5.2.2 Global Drugs for Xerostomia Forecasted Revenue by Application (2023-2028)
5.2.3 Global Drugs for Xerostomia Revenue Market Share by Application (2017-2028)
5.3 Global Drugs for Xerostomia Price by Application
5.3.1 Global Drugs for Xerostomia Price by Application (2017-2022)
5.3.2 Global Drugs for Xerostomia Price Forecast by Application (2023-2028)
6 North America
6.1 North America Drugs for Xerostomia Market Size by Type
6.1.1 North America Drugs for Xerostomia Sales by Type (2017-2028)
6.1.2 North America Drugs for Xerostomia Revenue by Type (2017-2028)
6.2 North America Drugs for Xerostomia Market Size by Application
6.2.1 North America Drugs for Xerostomia Sales by Application (2017-2028)
6.2.2 North America Drugs for Xerostomia Revenue by Application (2017-2028)
6.3 North America Drugs for Xerostomia Market Size by Country
6.3.1 North America Drugs for Xerostomia Sales by Country (2017-2028)
6.3.2 North America Drugs for Xerostomia Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Drugs for Xerostomia Market Size by Type
7.1.1 Europe Drugs for Xerostomia Sales by Type (2017-2028)
7.1.2 Europe Drugs for Xerostomia Revenue by Type (2017-2028)
7.2 Europe Drugs for Xerostomia Market Size by Application
7.2.1 Europe Drugs for Xerostomia Sales by Application (2017-2028)
7.2.2 Europe Drugs for Xerostomia Revenue by Application (2017-2028)
7.3 Europe Drugs for Xerostomia Market Size by Country
7.3.1 Europe Drugs for Xerostomia Sales by Country (2017-2028)
7.3.2 Europe Drugs for Xerostomia Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Drugs for Xerostomia Market Size by Type
8.1.1 Asia Pacific Drugs for Xerostomia Sales by Type (2017-2028)
8.1.2 Asia Pacific Drugs for Xerostomia Revenue by Type (2017-2028)
8.2 Asia Pacific Drugs for Xerostomia Market Size by Application
8.2.1 Asia Pacific Drugs for Xerostomia Sales by Application (2017-2028)
8.2.2 Asia Pacific Drugs for Xerostomia Revenue by Application (2017-2028)
8.3 Asia Pacific Drugs for Xerostomia Market Size by Region
8.3.1 Asia Pacific Drugs for Xerostomia Sales by Region (2017-2028)
8.3.2 Asia Pacific Drugs for Xerostomia Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Drugs for Xerostomia Market Size by Type
9.1.1 Latin America Drugs for Xerostomia Sales by Type (2017-2028)
9.1.2 Latin America Drugs for Xerostomia Revenue by Type (2017-2028)
9.2 Latin America Drugs for Xerostomia Market Size by Application
9.2.1 Latin America Drugs for Xerostomia Sales by Application (2017-2028)
9.2.2 Latin America Drugs for Xerostomia Revenue by Application (2017-2028)
9.3 Latin America Drugs for Xerostomia Market Size by Country
9.3.1 Latin America Drugs for Xerostomia Sales by Country (2017-2028)
9.3.2 Latin America Drugs for Xerostomia Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Drugs for Xerostomia Market Size by Type
10.1.1 Middle East and Africa Drugs for Xerostomia Sales by Type (2017-2028)
10.1.2 Middle East and Africa Drugs for Xerostomia Revenue by Type (2017-2028)
10.2 Middle East and Africa Drugs for Xerostomia Market Size by Application
10.2.1 Middle East and Africa Drugs for Xerostomia Sales by Application (2017-2028)
10.2.2 Middle East and Africa Drugs for Xerostomia Revenue by Application (2017-2028)
10.3 Middle East and Africa Drugs for Xerostomia Market Size by Country
10.3.1 Middle East and Africa Drugs for Xerostomia Sales by Country (2017-2028)
10.3.2 Middle East and Africa Drugs for Xerostomia Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Concordia
11.1.1 Concordia Corporation Information
11.1.2 Concordia Overview
11.1.3 Concordia Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Concordia Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Concordia Recent Developments
11.2 AMICI
11.2.1 AMICI Corporation Information
11.2.2 AMICI Overview
11.2.3 AMICI Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AMICI Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AMICI Recent Developments
11.3 Aurobindo Pharma Ltd
11.3.1 Aurobindo Pharma Ltd Corporation Information
11.3.2 Aurobindo Pharma Ltd Overview
11.3.3 Aurobindo Pharma Ltd Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Aurobindo Pharma Ltd Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Aurobindo Pharma Ltd Recent Developments
11.4 Impax Labs
11.4.1 Impax Labs Corporation Information
11.4.2 Impax Labs Overview
11.4.3 Impax Labs Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Impax Labs Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Impax Labs Recent Developments
11.5 Lannett Co Inc
11.5.1 Lannett Co Inc Corporation Information
11.5.2 Lannett Co Inc Overview
11.5.3 Lannett Co Inc Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Lannett Co Inc Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Lannett Co Inc Recent Developments
11.6 Padagis Us
11.6.1 Padagis Us Corporation Information
11.6.2 Padagis Us Overview
11.6.3 Padagis Us Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Padagis Us Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Padagis Us Recent Developments
11.7 Amneal Pharmaceuticals Pvt. Ltd.
11.7.1 Amneal Pharmaceuticals Pvt. Ltd. Corporation Information
11.7.2 Amneal Pharmaceuticals Pvt. Ltd. Overview
11.7.3 Amneal Pharmaceuticals Pvt. Ltd. Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Amneal Pharmaceuticals Pvt. Ltd. Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Amneal Pharmaceuticals Pvt. Ltd. Recent Developments
11.8 Bausch Health Companies Inc.
11.8.1 Bausch Health Companies Inc. Corporation Information
11.8.2 Bausch Health Companies Inc. Overview
11.8.3 Bausch Health Companies Inc. Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bausch Health Companies Inc. Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bausch Health Companies Inc. Recent Developments
11.9 GSK
11.9.1 GSK Corporation Information
11.9.2 GSK Overview
11.9.3 GSK Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 GSK Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 GSK Recent Developments
11.10 Jazz Pharmaceuticals plc
11.10.1 Jazz Pharmaceuticals plc Corporation Information
11.10.2 Jazz Pharmaceuticals plc Overview
11.10.3 Jazz Pharmaceuticals plc Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Jazz Pharmaceuticals plc Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Jazz Pharmaceuticals plc Recent Developments
11.11 Mission Pharmacal Company
11.11.1 Mission Pharmacal Company Corporation Information
11.11.2 Mission Pharmacal Company Overview
11.11.3 Mission Pharmacal Company Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Mission Pharmacal Company Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Mission Pharmacal Company Recent Developments
11.12 OraCoat
11.12.1 OraCoat Corporation Information
11.12.2 OraCoat Overview
11.12.3 OraCoat Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 OraCoat Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 OraCoat Recent Developments
11.13 Cumberland Pharmaceuticals, Inc.
11.13.1 Cumberland Pharmaceuticals, Inc. Corporation Information
11.13.2 Cumberland Pharmaceuticals, Inc. Overview
11.13.3 Cumberland Pharmaceuticals, Inc. Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Cumberland Pharmaceuticals, Inc. Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Cumberland Pharmaceuticals, Inc. Recent Developments
11.14 Fleet, C.B., Company
11.14.1 Fleet, C.B., Company Corporation Information
11.14.2 Fleet, C.B., Company Overview
11.14.3 Fleet, C.B., Company Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Fleet, C.B., Company Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Fleet, C.B., Company Recent Developments
11.15 Parnell Pharmaceuticals, Inc
11.15.1 Parnell Pharmaceuticals, Inc Corporation Information
11.15.2 Parnell Pharmaceuticals, Inc Overview
11.15.3 Parnell Pharmaceuticals, Inc Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Parnell Pharmaceuticals, Inc Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Parnell Pharmaceuticals, Inc Recent Developments
11.16 Clinigen
11.16.1 Clinigen Corporation Information
11.16.2 Clinigen Overview
11.16.3 Clinigen Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Clinigen Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Clinigen Recent Developments
11.17 Sun Pharm
11.17.1 Sun Pharm Corporation Information
11.17.2 Sun Pharm Overview
11.17.3 Sun Pharm Drugs for Xerostomia Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Sun Pharm Drugs for Xerostomia Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Sun Pharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Drugs for Xerostomia Industry Chain Analysis
12.2 Drugs for Xerostomia Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Drugs for Xerostomia Production Mode & Process
12.4 Drugs for Xerostomia Sales and Marketing
12.4.1 Drugs for Xerostomia Sales Channels
12.4.2 Drugs for Xerostomia Distributors
12.5 Drugs for Xerostomia Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Drugs for Xerostomia Industry Trends
13.2 Drugs for Xerostomia Market Drivers
13.3 Drugs for Xerostomia Market Challenges
13.4 Drugs for Xerostomia Market Restraints
14 Key Findings in The Global Drugs for Xerostomia Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【口腔乾燥症治療薬について】 口腔乾燥症、またはドライマウスは、唾液の分泌量が低下することによって引き起こされる症状であり、口腔内の潤いが不足することによる不快感や食事、話すことに対する支障をもたらします。患者にとって、この状態は非常に不快であり、さらに進行すると、虫歯、歯周病、口腔感染症のリスクも高まるため、適切な治療が求められます。 口腔乾燥症の原因は多岐にわたりますが、特に多く見られるのは、薬剤による副作用、放射線治療、自己免疫疾患、加齢といった要因です。たとえば、一部の抗うつ薬や抗ヒスタミン薬、利尿剤などは、唾液の分泌を抑制する作用があります。また、シェーグレン症候群などの自己免疫疾患では、唾液腺が攻撃されることにより劇的な乾燥が引き起こされます。 口腔乾燥症の治療薬は、主に唾液の分泌を促進することを目的としています。これらの薬は、患者の口腔内の環境を改善し、乾燥による不快感を軽減するために使用されます。市販されている乾燥症治療薬の代表的な成分には、ピロカルピンやセビメリンが含まれます。これらはコリン作動薬として、唾液腺に作用し、唾液の分泌を促します。ピロカルピンは経口投与や局所投与が可能であり、迅速に効果を発揮することが一般的です。セビメリンは特にシェーグレン症候群患者に対して効果的とされています。 薬剤以外の治療法も存在します。たとえば、湿潤性の口腔用ジェルやスプレー、または唾液代替品などの使用が推奨される場合があります。これらは物理的に口腔内の潤いを保ち、不快感を軽減する役割を果たします。さらに、口腔ケア用品の中には、敏感な口腔内を保護するための特別な成分が含まれている場合もあります。 口腔乾燥症の治療には、関連技術も重要な役割を果たしています。レーザー治療や電気刺激療法などが研究されており、これらは唾液腺の機能を刺激することを目的とします。これにより、薬剤に頼らずに唾液分泌を促進する手法として期待されています。 口腔乾燥症の患者に対する適切な治療は、多様な選択肢を考慮する必要があります。ひとりひとりの症状や原因は異なるため、医師との相談を通じて最適な治療法を見つけることが重要です。治療薬や関連技術は日々進化しており、新たな選択肢が提供される可能性もあります。 医学的な観点に加えて、患者の生活の質を向上させるためのサポートも重要です。適切な口腔ケアや栄養指導、ストレスマネジメントなどによって、口腔乾燥症の影響を受ける生活全般を改善することができます。自己管理技術を学ぶことで、患者は自らの状態をよりよく理解し、対処するためのスキルを身につけることが可能です。 口腔乾燥症は、多くの人々が直面する可能性のある問題ですが、適切な治療と支援を受けることで、その症状を管理し、生活の質を向上させることができるという点は非常に重要です。医療分野における研究は続いており、将来的にはより効果的な治療法が開発されることが期待されています。患者自身が自分の症状について理解し、専門家と密に連携を取りながら、治療を進めることが肝要です。口腔乾燥症に対する理解を深めることで、より良い治療戦略の選択と生活改善が可能となるでしょう。 |